Table 1 Characteristics of study population at the time of enrolment.

From: Distinguishing active from quiescent disease in ANCA-associated vasculitis using attenuated total reflection Fourier-transform infrared spectroscopy

  Active Disease (n = 25) Disease Remission (n = 38)
Mean Age (SD) 64 ± 11.9 67 ± 11.9
Sex   
Male 12/25 (48%) 20/38 (53%)
Female 13/25 (52%) 18/38 (47%)
Median serum creatinine (μmol/L) 216 (347–132) 122 (174–94)
Mean eGFR (mls/min/1.73m2) 22 (48–8) 47 (65–29)
Newly diagnosed disease 20/25 (80%)
Relapsing disease 5/25 (20%)
ANCA serotype   
MPO 9/25 (36%) 6/38 (16%)
PR3 12/25 (48%) 14/38 (37%)
Negative 4/25 (16%) 18/38 (47%)
BVAS 16 ± 9.6 0
Organ involvement   
Constitutional signs or symptoms 15/25 (60%)
Mucous membranes/Ophthalmic 6/25 (24%)
Cutaneous 1/25 (4%)
ENT 12/25 (48%)
Respiratory 6/25 (24%)
Cardiovascular 1/25 (4%)
Gastrointestinal 0
Renal 18/25 (72%)
Neurological 5/25 (20%)
Multisystem disease 17/25 (68%)
Renal limited 4/25 (16%)
Other laboratory salient laboratory results:   
Mean Haemoglobin (g/L) 100 ± 28.3 130 ± 13.4
Mean White cell count (109/L) 9 ± 3.7 7.2 ± 2.2
Mean Lymphocyte count (109/L) 1.2 ± 0.7 1.3 ± 0.6
Mean Neutrophil count (109/L) 7 ± 3.6 5.1 ± 2.2
Mean Platelet count (109/L) 309 ± 143.5 270 ± 80.6
Median CRP (mg/L) 42 (64.8–4.8) 2.6 (5.3–1.2)
Median ESR (mm/hr) 42 (80.5–9) 12 (19.8–5)
Median ESR (mm/hr) 42 (80.5–9) 12 (19.8–5)
Mean serum albumin (g/L) 34.7 ± 7.3 44.4 ± 2.9
Mean serum total protein (g/L) 62 ± 9.8 67.1 ± 4.7
Co-morbidities   
Ischaemic heart disease 1 (4%) 4 (11%)
Congestive cardiac failure 0 1 (3%)
Cerebrovascular disease 1 (4%) 2 (5%)
Hypertension 5 (20%) 18 (47%)
Peripheral vascular disease 0 1(3%)
Diabetes Mellitus 2 (8%) 3 (8%)
Chronic pulmonary disease 6 (24%) 5 (13%)
Chronic liver disease 0 0
Connective tissue disease 1 (4%)* 0
Malignancy 2 (8%)** 1 (3%)***
Immunosuppression   
None 8 (26%) 7 (18%)
Prednisolone**** 14 (56%) 15 (39%)
Methylprednisolone 7 (28%) 0
Rituximab within the preceding 6 months 1 (4%) 13 (34%)
Cyclophosphamide 2 (8%) 2 (5%)
Azathioprine 0 6 (16%)
Mycophenolate 0 4 (11%)
Methotrexate 0 1 (3%)
  1. eGFR estimated glomerular filtration rate, ANCA anti-neutrophil cytoplasmic autoantibody, MPO myeloperoxidase, PR3 proteinase-3, ESR erythrocyte sedimentary rate, CRP C-reactive protein.
  2. *One case or rheumatoid arthritis in remission, **One case of non-metastatic prostate cancer in remission & one case of colonic tubular adenoma, ***One case of non-melanoma skin cancer, **** Amongst the remission cohort a daily dose of prednisolone ≥ 5 mg was considered significant.